We have a very deep management team each with over 25 years of expertise in our related fields.
CHIEF EXECUTIVE OFFICER
Andrew has 30 years of experience in the life sciences and technology industries as CFO, CEO, & Co-founder of public & private companies. He is experienced in harnessing the chaos of small organizations through to IPOs. Andrew returns to SQI from ATTWILL Medical Solutions (AMS) where he was a Managing Partner – AMS is a developer of their own vascular devices such as Haloguard™, approved by the FDA in September 2020. AMS is also a contract provider of lyophilization services to the life sciences and biopharma industry. Previously, he was CEO of SQI Diagnostics for 7 years, following seven years as CFO, taking SQI public in 2007. Andrew’s career was launched as an Officer in the Canadian Armed Forces for 13 years where, for 9 years, he led applied research and development projects focussed in soldier survival in a variety of harsh environments. He moved on to be a key team member or co-founder in a number of technology start-ups (FORGE Hydrocarbons Corp, Planet People (Concrobium branded products), Norigen Communications and Allstream™. He gained valuable capital markets and advisory experience working in equity research at Scotia Capital and leading EY Corporate Finance’s Life Sciences advisory segment. He has raised and managed significant investor capital, helped grow the operations of, and exit multiple businesses and created mutually successful partnerships across a broad spectrum of businesses.
CHIEF SCIENTIFIC OFFICER
Eric Brouwer, PhD
Eric Brouwer, PhD, is the Chief Scientific Officer of SQI Diagnostics, Inc. and has served in that position since October 2017. From April 2015 to May 2017, Mr. Brouwer was the Chief Scientific Officer of Trinity Biotech plc and then CEO of its subsidiary, Fiomi. From 2003 to 2015, Mr. Brouwer held various positions in Research and Development at Abbott Point of Care, including Senior Manager Research and Director of Assay Research and Development. While at Abbott, Mr. Brouwer developed and help launch a number of point of care diagnostics products, was the recipient of two divisional President’s Awards (2006, 2008) and the prestigious Chairman’s Award in 2007 and served as a member of the Abbott Scientific Governing Board. Mr. Brouwer also was a member of the Ottawa Life Sciences Council 2013 to 2014. From 2000 to 2003, Mr. Brouwer was a Senior Scientist at the point-of-care diagnostic innovator and industry leader i-STAT, prior to the acquisition of i-STAT by Abbott. Mr. Brouwer holds three U.S. patents and has authored over 30 peer-reviewed journal articles. Mr. Brouwer holds multiple degrees in chemistry from Queen’s University (BSc(Hons)), University of British Columbia (MSc) and Carleton University (PhD) and a post-doctoral fellowship at the University of Durham (UK).
CHIEF FINANCIAL OFFICER
Morlan Reddock, is the Chief Financial Officer of SQI Diagnostics, Inc. and has served in that position since March 2020. From July 2017 to October 2019, Mr. Reddock served as the Director of Finance for the Greater Toronto Airports Authority (GTAA) and from December 2017 to October 2019 served concurrently as Acting CFO for the GTAA subsidiary Malton Gateway. From May 2016 to July 2017, Mr. Reddock served as the Vice President Finance for Ronnex Distribution. From 2008 to 2015 Mr. Reddock was the Director of Finance, Treasury and Investor Relations for SiriusXM Canada. From 2005 to 2008, Mr. Reddock was Manager of Finance, Acquisitions and Planning for Direct Energy. From 1999 to 2005, Mr. Reddock held positions in Accounting and Finance. Mr. Reddock is a member of the Chartered Professional Accountants of Ontario, The CFO Leadership Council (Toronto Chapter) and Financial Executives International (FEI). Mr. Reddock is a CPA, CFA, and holds an MBA from the Rotman School of Management, a Bachelor of Engineering degree from Concordia University and has completed Executive Leadership training at the Ivey School of Business.